NSF/FDA SIR: 3D Engineered Tissue Models for In Vitro Safety Testing of Nanoparticles

这个为期一年的常驻学者项目的目标是开发增强的体外测试方法，以严格评估纳米颗粒的安全性，纳米颗粒正越来越多地被用作医疗器械的组件。为了应对这一新出现的需求，美国食品和药物管理局(FDA)已经开始努力表征纳米颗粒的生物效应。特别是，设备和放射健康中心(CDRH)的科学与工程实验室办公室(OSEL)对纳米技术和评估纳米毒性有着浓厚的兴趣。密歇根大学(UMich)的PI实验室长期以来一直致力于表征定义良好且一致的工程化组织中的细胞功能，这些组织由直接嵌入3D蛋白质基质的细胞组成，也一直在研究这些系统中细胞与纳米颗粒的相互作用。这种工程化组织模仿了天然组织3D环境的重要方面，因此有可能提供传统2D培养或动物研究无法提供的关于纳米颗粒生物相容性的信息。

Abstract#1237549StegemannThe goal of this 1-year Scholar-in-Residence project is to develop enhanced in vitro testing methods to rigorously evaluate the safety of nanoparticles, which are increasingly being used as components of medical devices. In response to this emerging need, the U.S. Food and Drug Administration (FDA) has initiated efforts to characterize the biological effects of nanoparticles. In particular, the Office of Science and Engineering Laboratories (OSEL) in the Center for Devices and Radiological Health (CDRH) has a strong interest in nanotechnology and evaluating nanotoxicity. The PI's lab at the University of Michigan (UMich) has a longstanding interest in characterizing cell function in well defined and consistent engineered tissues composed of cells embedded directly in a 3D protein matrix, and also has been working on cell-nanoparticle interactions in these systems. Such engineered tissues mimic important aspects of the 3D environment of native tissues, and therefore have the potential to provide information on nanoparticle biocompatibility that is not available from conventional 2D cultures or animal studies.